Skip to main content

CorMedix Inc 8-K, filed Nov 16, 2026

CorMedix Inc. (CRMD)

8-K 2026-11-16 For: 2026-11-12
View Original
Added on November 16, 2026

About this 8-K

CorMedix Inc filed this 8-K on November 16, 2026, reporting on events of November 12, 2026.

CorMedix expects its proposed acquisition of substantially all Heron Therapeutics assets to close in the first quarter of 2027. Third-quarter revenue was $54.5 million and adjusted EBITDA was $3.1 million; 2026 revenue guidance remained $325 million to $345 million. AI summary

Items reported

  • Item 7.01: Regulation FD disclosure
  • Item 9.01: Financial statements and exhibits